Physician profile
Robert James Simon
NPI 1629421664
$3,499.96
in general payments reported to CMS, 2019-2025
18 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $390 · 2023: $824 · 2024: $971 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $704.58 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $614.17 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $465.73 | 2022-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $449.19 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $237.70 | 2025 | |
| Axsome Therapeutics, INC. | $231.50 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $200.53 | 2025 | Rexulti |
| Tris Pharma INC | $131.21 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $124.62 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $107.86 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.00 | 2025 | Caplyta |
| Corium, LLC | $43.32 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $41.91 | 2024-2025 | Qelbree |
| Neuronetics, INC. | $24.87 | 2023 | Neurostar Tms Therapy System |
| Jazz Pharmaceuticals INC. | $21.09 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.44 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.14 | 2023 | Hetlioz, Fanapt |
| Owp Pharmaceuticals, INC. | $17.10 | 2023 | Subvenite, Lamotrigine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.